These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 12678218

  • 1. The ALLHAT Trial. Diuretics are still the preferred initial drugs for high blood pressure.
    Vidt DG.
    Cleve Clin J Med; 2003 Mar; 70(3):263-9. PubMed ID: 12678218
    [Abstract] [Full Text] [Related]

  • 2. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
    JAMA; 2000 Apr 19; 283(15):1967-75. PubMed ID: 10789664
    [Abstract] [Full Text] [Related]

  • 3. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, Goff D, Leenen F, Mohiuddin S, Papademetriou V, Proschan M, Ellsworth A, Golden J, Colon P, Crow R, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group.
    Circulation; 2006 May 09; 113(18):2201-10. PubMed ID: 16651474
    [Abstract] [Full Text] [Related]

  • 4. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Wright JT, Harris-Haywood S, Pressel S, Barzilay J, Baimbridge C, Bareis CJ, Basile JN, Black HR, Dart R, Gupta AK, Hamilton BP, Einhorn PT, Haywood LJ, Jafri SZ, Louis GT, Whelton PK, Scott CL, Simmons DL, Stanford C, Davis BR.
    Arch Intern Med; 2008 Jan 28; 168(2):207-17. PubMed ID: 18227370
    [Abstract] [Full Text] [Related]

  • 5. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    JAMA; 2002 Dec 18; 288(23):2981-97. PubMed ID: 12479763
    [Abstract] [Full Text] [Related]

  • 6. [Old or new antihypertensive drugs? Consequences from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial].
    Düsing R.
    Dtsch Med Wochenschr; 2003 Jan 31; 128(5):214-6. PubMed ID: 12557115
    [No Abstract] [Full Text] [Related]

  • 7. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
    Davis BR, Kostis JB, Simpson LM, Black HR, Cushman WC, Einhorn PT, Farber MA, Ford CE, Levy D, Massie BM, Nawaz S, ALLHAT Collaborative Research Group.
    Circulation; 2008 Nov 25; 118(22):2259-67. PubMed ID: 19001024
    [Abstract] [Full Text] [Related]

  • 8. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Black HR, Davis B, Barzilay J, Nwachuku C, Baimbridge C, Marginean H, Wright JT, Basile J, Wong ND, Whelton P, Dart RA, Thadani U, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Diabetes Care; 2008 Feb 25; 31(2):353-60. PubMed ID: 18000186
    [Abstract] [Full Text] [Related]

  • 9. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T.
    Arch Intern Med; 2005 Apr 25; 165(8):936-46. PubMed ID: 15851647
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
    Johnson K, Oparil S, Davis BR, Tereshchenko LG.
    J Am Heart Assoc; 2019 Apr 16; 8(8):e011961. PubMed ID: 30943832
    [Abstract] [Full Text] [Related]

  • 12. Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT.
    Bangalore S, Davis BR, Cushman WC, Pressel SL, Muntner PM, Calhoun DA, Kostis JB, Whelton PK, Probstfield JL, Rahman M, Black HR, ALLHAT Collaborative Research Group.
    Am J Med; 2017 Apr 16; 130(4):439-448.e9. PubMed ID: 27984005
    [Abstract] [Full Text] [Related]

  • 13. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
    Einhorn PT, Davis BR, Massie BM, Cushman WC, Piller LB, Simpson LM, Levy D, Nwachuku CE, Black HR, ALLHAT Collaborative Research Group.
    Am Heart J; 2007 Jan 16; 153(1):42-53. PubMed ID: 17174636
    [Abstract] [Full Text] [Related]

  • 14. Are thiazide diuretics preferred as first-line therapy for hypertension? An appraisal of The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Scott I, Stowasser M.
    Intern Med J; 2003 Jul 16; 33(7):327-30. PubMed ID: 12823686
    [No Abstract] [Full Text] [Related]

  • 15. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
    Rahman M, Ford CE, Cutler JA, Davis BR, Piller LB, Whelton PK, Wright JT, Barzilay JI, Brown CD, Colon PJ, Fine LJ, Grimm RH, Gupta AK, Baimbridge C, Haywood LJ, Henriquez MA, Ilamaythi E, Oparil S, Preston R, ALLHAT Collaborative Research Group.
    Clin J Am Soc Nephrol; 2012 Jun 16; 7(6):989-1002. PubMed ID: 22490878
    [Abstract] [Full Text] [Related]

  • 16. Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
    Oparil S, Davis BR, Cushman WC, Ford CE, Furberg CD, Habib GB, Haywood LJ, Margolis K, Probstfield JL, Whelton PK, Wright JT, ALLHAT Collaborative Research Group.
    Hypertension; 2013 May 16; 61(5):977-86. PubMed ID: 23529173
    [Abstract] [Full Text] [Related]

  • 17. Alpha-blockers and congestive heart failure: early termination of an arm of the ALLHAT trial.
    Vidt DG.
    Cleve Clin J Med; 2000 Jun 16; 67(6):429-33. PubMed ID: 10860225
    [Abstract] [Full Text] [Related]

  • 18. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, Leenen FH, Louis GT, Margolis KL, Mathis DE, Moloo J, Nwachuku C, Panebianco D, Parish DC, Pressel S, Simmons DL, Thadani U, ALLHAT Collaborative Research Group.
    Arch Intern Med; 2005 Jun 27; 165(12):1401-9. PubMed ID: 15983290
    [Abstract] [Full Text] [Related]

  • 19. [Are all antihypertensive agents equal? Cardiovascular events in hypertensive patients randomized to treatment with doxazosin or chlorthalidone. The ALLHAT study].
    Schillaci G, Verdecchia P.
    Ital Heart J Suppl; 2000 Sep 27; 1(9):1215-7. PubMed ID: 11140297
    [No Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Heidenreich PA, Davis BR, Cutler JA, Furberg CD, Lairson DR, Shlipak MG, Pressel SL, Nwachuku C, Goldman L.
    J Gen Intern Med; 2008 May 27; 23(5):509-16. PubMed ID: 18228109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.